Mirum Pharmaceuticals

MIRM

Market cap $3.52B

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?

Mirum Pharmaceuticals has been a big winner in 2025 thanks to the success of its flagship product, Livmarli. Livmarli should continue to gain momentum in 2026.

Mirum Pharmaceuticals, Inc. (MIRM) Presents at Evercore 8th Annual Healthcare Conference Transcript

Mirum enrolls the first participant in its phase II BLOOM study investigating MRM-3379 for treating Fragile X syndrome.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that the first participant has been enrolled in the BLOOM Phase 2 clinical study evaluating MRM-3379 in Fragile X syndrome (FXS). Caused by a mutation of the FMR1 gene, FXS is the most common inherited form of intellectual disability and autism spectrum disorder and affects an estimated 50,000 males in the U.S. and E.U. There are currently no approved therapies for t.

Biotech stocks have a strong presence on the elite IBD 50 list of growth stocks.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences: 8th Annual Evercore HealthCONx Conference on Tuesday, December 2nd Company presentation - Tuesday, December 2nd starting at 2:10 p.m. ET Citi's 2025 Global Heal.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharma Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD's The Liver Meeting®.

Mirum posts third-quarter profit and stronger revenues on surging Livmarli demand, while tightening its 2025 sales outlook.